- See a full list of publications
- Browse activities and projects
- Explore connections, collaborators, related work and more
Mark Sculpher is Professor of Health Economics and is Team Leader of the Programme on Economic Evaluation and Health Technology Assessment. He is also Co-Director of the Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU). He has been based at York University since 1997.
Between 1988 and 1997, he worked at the Health Economics Research Group at Brunel University; during 1998 he was a visitor in the Department of Clinical Epidemiology and Biostatistics at McMaster University in Canada.
Mark has worked on economic evaluations of a range of technologies including heart disease and various cancers. He has also contributed to methods in the field, in particular relating to decision analytic modelling and handling uncertainty. He has over 280 peer-reviewed publications and is a co-author of two major text books in the area: Methods for the economic evaluation of health care programmes (OUP, 2015 with Drummond, Claxton, Torrance, and Stoddart) and Decision modelling for health economic evaluation (OUP, 2006 with Briggs and Claxton). He was also a member of the Second Panel on Cost-Effectiveness in Health and Medicine.
Mark was a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee (2004-8), the NICE Public Health Interventions Advisory Committee (2006-9) and the NICE Diagnostics Advisory Committee (2010-20). He chaired NICE's 2004 Task Group on methods guidance for economic evaluation and was a member of the Methods Working Party for the 2008 update of this guidance. He was a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme (2007-10), the UK National Institute for Health Research (NIHR)/Medical Research Council (MRC) Methodology Research Panel (2008-11) and the MRC-NIHR Methodology Research Advisory Group (2016-20). He was a member of the NIHR Policy Research Programme’s Commissioning Panel (2011-14). Mark is a NIHR Senior Investigator (Emeritus) and is a former President of the International Society of Pharmacoeconomics and Outcomes Research.
Recent national and international advisory roles include the Singapore Agency for Care Effectiveness International Advisory Panel (2017-18); UK Health Select Committee Availability of Orkambi on the NHS inquiry (2018-19); Portuguese National Authority of Medicines and Health Products (2018-20).
Centre for Health Economics
- Decision analytic modelling for economic evaluation - Course leader
- Advanced methods for cost-effective analysis: meeting decision-makers' requirements - Co course leader
- Foundations of economic evaluation in health care - Co course leader
We now have estimates of the marginal productivity of the NHS: so what? Health Economists’ Study Group, York, UK. January 2019.
A framework for value assessment of new antimicrobials. Wellcome Forum on Value Assessment and Contracting for Antibiotics, London. February 2019.
Beyond cost-effectiveness analysis: how can we make global value assessments more flexible and comprehensive? Issues Panel, ISPOR New Orleans, USA. May 2019.
Life experiences of managed care agreements for high cost drugs. International Health Technology Assessment Workshop, Taiwan. June 2019.
Striving for a societal perspective for economic evaluation. iHEA Congress, Basel, Switzerland. July 2019.
Discussion: moving from estimation to decisions in complex interventions. iHEA Congress, Basel, Switzerland. July 2019.
Health technology appraisal methods and processes for antibiotics: developments in the UK and implications for Europe. ISPOR, Copenhagen. November 2019.
The principles of good decision making for funding of healthcare. Monash Health Economics Forum, Monash University, Kuala Lumpur, Malaysia. November 2019.
Determining the value of healthcare interventions. Anaesthesia Research, York. December 2019.